Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA – Get Free Report) shares were down 5.2% during trading on Monday. The stock traded as low as $0.5215 and last traded at $0.5701. Approximately 233,808 shares traded hands during mid-day trading, a decline of 76% from the average session volume of 984,912 shares. The stock had previously closed at $0.6013.
Kairos Pharma Price Performance
The stock’s fifty day moving average price is $1.60 and its 200-day moving average price is $2.64. The firm has a market cap of $1.95 million, a price-to-earnings ratio of -0.29 and a beta of 1.45.
Kairos Pharma (NYSEAMERICAN:KAPA – Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($0.42) earnings per share for the quarter. As a group, equities research analysts predict that Kairos Pharma, Ltd. will post -2.59 EPS for the current fiscal year.
About Kairos Pharma
Kairos Pharma is a clinical-stage biopharmaceutical company focused on developing therapies for cancer, particularly treatments intended to address resistance to existing immunotherapies and other oncology treatments. The company’s work centers on immuno-oncology and the development of investigational drug candidates for patients with difficult-to-treat cancers.
Kairos Pharma is advancing a pipeline of experimental therapies designed to modify the tumor microenvironment and improve the body’s immune response against cancer.
See Also
- Five stocks we like better than Kairos Pharma
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
Receive News & Ratings for Kairos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kairos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
